Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements

Elisabetta Falvo, Elisa Tremante, Alessandro Arcovito, Massimiliano Papi, Nadav Elad, Alberto Boffi, Veronica Morea, Giamaica Conti, Giuseppe Toffoli, Giulio Fracasso, Patrizio Giacomini, Pierpaolo Ceci

Research output: Contribution to journalArticle

Abstract

A novel human ferritin-based nanocarrier, composed of 24 modified monomers able to auto-assemble into a modified protein cage, was produced and used as selective carrier of anti-tumor payloads. Each modified monomer derives from the genetic fusion of two distinct modules, namely the heavy chain of human ferritin (HFt) and a stabilizing/protective PAS polypeptide sequence rich in proline (P), serine (S), and alanine (A) residues. Two genetically fused protein constructs containing PAS polymers with 40- and 75-residue lengths, respectively, were compared. They were produced and purified as recombinant proteins in Escherichia coli at high yields. Both preparations were highly soluble and stable in vitro as well as in mouse plasma. Size-exclusion chromatography, dynamic light scattering, and transmission electron microscopy results indicated that PASylated ferritins are fully assembled and highly monodispersed. In addition, yields and stability of encapsulated doxorubicin were significantly better for both HFt-PAS proteins than for wild-type HFt. Importantly, PAS sequences considerably prolonged the half-life of HFt in the mouse bloodstream. Finally, our doxorubicin-loaded nanocages preserved the pharmacological activity of the drug. Taken together, these results indicate that both of the developed HFt-PAS fusion proteins are promising nanocarriers for future applications in cancer therapy.

Original languageEnglish
Pages (from-to)514-522
Number of pages9
JournalBiomacromolecules
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 8 2016

Fingerprint

Bearings (structural)
Pharmacokinetics
Ferritins
Encapsulation
Proline
Alanine
Doxorubicin
Serine
Fusion reactions
Proteins
Monomers
Recombinant proteins
Size exclusion chromatography
Polypeptides
Dynamic light scattering
Light transmission
Escherichia coli
Tumors
Transmission electron microscopy
Plasmas

ASJC Scopus subject areas

  • Bioengineering
  • Materials Chemistry
  • Polymers and Plastics
  • Biomaterials

Cite this

Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. / Falvo, Elisabetta; Tremante, Elisa; Arcovito, Alessandro; Papi, Massimiliano; Elad, Nadav; Boffi, Alberto; Morea, Veronica; Conti, Giamaica; Toffoli, Giuseppe; Fracasso, Giulio; Giacomini, Patrizio; Ceci, Pierpaolo.

In: Biomacromolecules, Vol. 17, No. 2, 08.02.2016, p. 514-522.

Research output: Contribution to journalArticle

Falvo, Elisabetta ; Tremante, Elisa ; Arcovito, Alessandro ; Papi, Massimiliano ; Elad, Nadav ; Boffi, Alberto ; Morea, Veronica ; Conti, Giamaica ; Toffoli, Giuseppe ; Fracasso, Giulio ; Giacomini, Patrizio ; Ceci, Pierpaolo. / Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. In: Biomacromolecules. 2016 ; Vol. 17, No. 2. pp. 514-522.
@article{654ad1b9b0e44733b10e202392186449,
title = "Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements",
abstract = "A novel human ferritin-based nanocarrier, composed of 24 modified monomers able to auto-assemble into a modified protein cage, was produced and used as selective carrier of anti-tumor payloads. Each modified monomer derives from the genetic fusion of two distinct modules, namely the heavy chain of human ferritin (HFt) and a stabilizing/protective PAS polypeptide sequence rich in proline (P), serine (S), and alanine (A) residues. Two genetically fused protein constructs containing PAS polymers with 40- and 75-residue lengths, respectively, were compared. They were produced and purified as recombinant proteins in Escherichia coli at high yields. Both preparations were highly soluble and stable in vitro as well as in mouse plasma. Size-exclusion chromatography, dynamic light scattering, and transmission electron microscopy results indicated that PASylated ferritins are fully assembled and highly monodispersed. In addition, yields and stability of encapsulated doxorubicin were significantly better for both HFt-PAS proteins than for wild-type HFt. Importantly, PAS sequences considerably prolonged the half-life of HFt in the mouse bloodstream. Finally, our doxorubicin-loaded nanocages preserved the pharmacological activity of the drug. Taken together, these results indicate that both of the developed HFt-PAS fusion proteins are promising nanocarriers for future applications in cancer therapy.",
author = "Elisabetta Falvo and Elisa Tremante and Alessandro Arcovito and Massimiliano Papi and Nadav Elad and Alberto Boffi and Veronica Morea and Giamaica Conti and Giuseppe Toffoli and Giulio Fracasso and Patrizio Giacomini and Pierpaolo Ceci",
year = "2016",
month = "2",
day = "8",
doi = "10.1021/acs.biomac.5b01446",
language = "English",
volume = "17",
pages = "514--522",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements

AU - Falvo, Elisabetta

AU - Tremante, Elisa

AU - Arcovito, Alessandro

AU - Papi, Massimiliano

AU - Elad, Nadav

AU - Boffi, Alberto

AU - Morea, Veronica

AU - Conti, Giamaica

AU - Toffoli, Giuseppe

AU - Fracasso, Giulio

AU - Giacomini, Patrizio

AU - Ceci, Pierpaolo

PY - 2016/2/8

Y1 - 2016/2/8

N2 - A novel human ferritin-based nanocarrier, composed of 24 modified monomers able to auto-assemble into a modified protein cage, was produced and used as selective carrier of anti-tumor payloads. Each modified monomer derives from the genetic fusion of two distinct modules, namely the heavy chain of human ferritin (HFt) and a stabilizing/protective PAS polypeptide sequence rich in proline (P), serine (S), and alanine (A) residues. Two genetically fused protein constructs containing PAS polymers with 40- and 75-residue lengths, respectively, were compared. They were produced and purified as recombinant proteins in Escherichia coli at high yields. Both preparations were highly soluble and stable in vitro as well as in mouse plasma. Size-exclusion chromatography, dynamic light scattering, and transmission electron microscopy results indicated that PASylated ferritins are fully assembled and highly monodispersed. In addition, yields and stability of encapsulated doxorubicin were significantly better for both HFt-PAS proteins than for wild-type HFt. Importantly, PAS sequences considerably prolonged the half-life of HFt in the mouse bloodstream. Finally, our doxorubicin-loaded nanocages preserved the pharmacological activity of the drug. Taken together, these results indicate that both of the developed HFt-PAS fusion proteins are promising nanocarriers for future applications in cancer therapy.

AB - A novel human ferritin-based nanocarrier, composed of 24 modified monomers able to auto-assemble into a modified protein cage, was produced and used as selective carrier of anti-tumor payloads. Each modified monomer derives from the genetic fusion of two distinct modules, namely the heavy chain of human ferritin (HFt) and a stabilizing/protective PAS polypeptide sequence rich in proline (P), serine (S), and alanine (A) residues. Two genetically fused protein constructs containing PAS polymers with 40- and 75-residue lengths, respectively, were compared. They were produced and purified as recombinant proteins in Escherichia coli at high yields. Both preparations were highly soluble and stable in vitro as well as in mouse plasma. Size-exclusion chromatography, dynamic light scattering, and transmission electron microscopy results indicated that PASylated ferritins are fully assembled and highly monodispersed. In addition, yields and stability of encapsulated doxorubicin were significantly better for both HFt-PAS proteins than for wild-type HFt. Importantly, PAS sequences considerably prolonged the half-life of HFt in the mouse bloodstream. Finally, our doxorubicin-loaded nanocages preserved the pharmacological activity of the drug. Taken together, these results indicate that both of the developed HFt-PAS fusion proteins are promising nanocarriers for future applications in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84957916289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957916289&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.5b01446

DO - 10.1021/acs.biomac.5b01446

M3 - Article

VL - 17

SP - 514

EP - 522

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 2

ER -